An Open-label, Multi-center, Phase 1b Study to Investigate the Safety and Tolerability of SLC-0111 (WBI-5111) in Combination With Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Subjects Positive for Carbonic Anhydrase IX (CAIX)
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 08 Mar 2018
At a glance
- Drugs SLC 0111 (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions
- Sponsors SignalChem Lifesciences
- 22 Feb 2018 Status changed from planning to not yet recruiting.
- 08 Dec 2014 New trial record
- 04 Dec 2014 This trial is expected to be initiated later in 2015, according to a SignalChem Lifesciences media release.